Table 2.
| High-risk lesion | Upgrade rate to malignancy | Upgrade Rate to Malignancy by Core-Needle Biopsy (CNB) or Vacuum-Assisted Biopsy (VAB) |
|---|---|---|
| Lobular neoplasia (LN) | 17% (95% CI 13–21%) | Overall range 0–40% |
| Atypical lobular hyperplasia (ALH) | 12% (95% CI 5–21%) |
CNB (14G) 16% VAB (9G): 6–25.4% for ALH and LCIS |
| Lobular carcinoma in situ (LCIS) | 22% (95% CI 14–31%) |
CNB (14G) 25% VAB: 6–25.4% for ALH and LCIS |
| Atypical Intraductal Epithelial Proliferation (AIDEP) | 28% (95% CI 24–31%) |
CNB (14G) 31% VAB (14G) 24% & (11G) 19% |
| Flat epithelial atypia (FEA) | 11% (95% CI 8–14%) |
CNB (14G) 10–21% VAB (11G) 6% |
| Papillary lesion (PL) | 12% (95% CI 10–15%) | 13.2% |
| No atypia | 7% (95% CI 4–10%) |
CNB (14G) mean 3.9% (range 0–20%) VAB (11G) mean 7.7% (range 0–18.3%) |
| Atypia | 32% (95% CI 23–41%) |
CNB (14G) mean 46.7% (range 6.7–71.4%) VAB (11G) mean 33% (range 0–71%) |
| Radial Scar or Complex Sclerosing Lesions (RS/CSL) | 8% (95% CI 6–11%) | |
| No atypia | 6% (95% CI 2–13%) |
CNB (14G) 9% (1–28%) VAB (11G) 1% (0–10%) |
| Atypia | 18% (95% CI 8–32%) |
CNB (14G) 33% VAB (11G) 2% (range 0–18%) |